The immune response to SARS-CoV-2 in COVID-19 as a recall response susceptible to immune imprinting: A prospective cohort study.

Publication date: Jan 20, 2025

The antibody response to SARS-CoV-2 does not follow the immunoglobulin isotype pattern of primary responses, conflicting with the current interpretation of COVID-19. Prospective cohort study of 191 SARS-CoV-2 infection cases and 44 controls from the second wave of COVID-19. The study stratified patients by severity and analyzed the trajectories of SARS-CoV-2 antibodies and multiple immune variables. Isotype-specific antibody time course profiles to SARS-CoV-2 revealed a pattern of recall response in 94. 2 % of cases. The time course profiles of plasmablasts, B cells, cTfh high-resolution subsets, and cytokines indicated a secondary response. The transcriptomic data showed that this cohort is strictly comparable to contemporary cohorts. In most cases, the immune response to SARS-CoV-2 is a recall response. This constitutes a favorable scenario for most COVID-19 cases to be subjected to immune imprinting by endemic coronavirus, which, in turn, can influence the immune response to SARS-CoV-2.

Open Access PDF

Concepts Keywords
Antibodies Antibody-dependent-enhancement
Contemporary COVID-19
Coronavirus cTfh
Plasmablasts Immune imprinting
Transcriptomic Original antigenic sin
Plasmablast
SARS-CoV-2
Spectral flow cytometry

Semantics

Type Source Name
disease IDO immune response
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease IDO production
disease IDO process
disease MESH Inflammation
disease MESH antibody dependent enhancement
disease MESH uncertainty
disease MESH Common Cold
disease MESH infection
drug DRUGBANK Huperzine B
disease IDO blood
drug DRUGBANK Edetic Acid
disease IDO history
drug DRUGBANK Oxygen
disease IDO symptom
disease MESH clinical progression
disease IDO assay
disease IDO host
drug DRUGBANK Coenzyme M
disease IDO protein
disease IDO pathogen
disease MESH re infection
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH lymphopenia
disease MESH pneumonia
disease MESH anomalies
disease IDO cell
disease MESH viral infections
disease MESH dengue
drug DRUGBANK Ranitidine
drug DRUGBANK Etoperidone
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Atropine
drug DRUGBANK Sulfasalazine
drug DRUGBANK Sodium hydroxide
drug DRUGBANK Ibuprofen
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Ethanol
disease IDO immunosuppression
disease MESH Hypertension
disease MESH Heart failure
disease MESH Chronic Kidney Failure
disease MESH Liver Cirrhosis
drug DRUGBANK Angiotensin II
disease MESH Weight loss
disease MESH Chest Pain
disease MESH Anosmia
disease MESH Cacosmia
disease MESH Confusion
drug DRUGBANK Creatinine
drug DRUGBANK Urea
drug DRUGBANK Fibrinogen Human
drug DRUGBANK Prothrombin

Original Article

(Visited 1 times, 1 visits today)